Skip to main content

Table 3 Summary of overall AEs reported in the 24-week, double-blind phase [10]a

From: Benefits Beyond Headache Days With OnabotulinumtoxinA Treatment: A Pooled PREEMPT Analysis

n (%) OnabotulinumtoxinA (n = 687) Placebo (n = 692)
All AEs 429 (62.4) 358 (51.7)
TRAEs 202 (29.4) 88 (12.7)
SAEs 33 (4.8) 16 (2.3)
Serious TRAEs 1 (0.1) 0 (0.0)
Discontinuations related to AEs 26 (3.8) 8 (1.2)
Death 0 (0.0) 0 (0.0)
  1. AE adverse event, SAE serious adverse event, TRAE treatment-related adverse event
  2. aReproduced with permission from John Wiley & Sons Inc. Dodick DW et al., Headache. 2010;50:921–936